Bojungikki-tang extracts on immune function after concurrent chemoradiation therapy in patients with cervical cancer : a pilot study
- Conditions
- Not Applicable
- Registration Number
- KCT0001444
- Lead Sponsor
- Comprehensive and Integrative Medical Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Female
- Target Recruitment
- 20
1. Patients with cervical cancer who have received chemoradiation before 1-6 month.
2. ECOG performance 0-2
3. Age: 30-70
4. No disability of cognitive function
5. Patients who can be possible to follow up during this study
6. Patients who have signed an approved informed consent
1. Patietns who have a history of hypersensitivity after taking Bojungikki-tang granules.
2. Patients who have an autoimmune diseases such as rheumatoid arthritis, Hashimoto's thyroiditis , Bechet's disease , etc.
3. Diabetes
4. Patients who have significant psychiatric history or currently suffering from such diseases.
5. Severe liver or kidney failure at liver and kidney function test.
6. Patients who have alcohol or drug abuse history
7. Patients who did not signe an approved informed consent.
8. Patients who are not suitable for this study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in CD 3, CD 4, CD 8, CD 19, CD 56
- Secondary Outcome Measures
Name Time Method quality of life with EORTC( European Organization for Research and Treatment of Cancer) QLQ-30, FSS(Fatigue severity scale);Complete Blood Count, Blood chemical test